RxDoctor Payments Data

William Ballard, MD

Cardiovascular Disease · Atlanta, GANPI 1902812993

Payments from drug & device makers

$20,114in general payments, 2019–2025

Across 97 payments — averaging $207.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$17K
  • Abiomed$881
  • Abbott$524
  • Novartis$490
  • Boston Scientific$430
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$209
  • plus $858 from 16 others

What the payments were for

  • Food & beverage$3,392100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,114 in reported general payments places this provider in the 85th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$89,434
Medicare patients
327
Services billed
663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban38$60,263
ClopidogrelClopidogrel Bisulfate116$1,677
Metoprolol Succinate75$1,268
Atorvastatin Calcium102$903
Rosuvastatin Calcium41$653
Ezetimibe32$411
Metoprolol Tartrate84$354
SotalolSotalol Hcl13$298
Amlodipine Besylate52$271
Isosorbide Mononitrate ErIsosorbide Mononitrate16$248
Nitroglycerin25$214
Pravastatin Sodium18$214
Warfarin Sodium27$208
Lisinopril34$170
Losartan Potassium27$137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$60,26338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →